We are live on ! Find out more
IRD

Opus Genetics

79 hedge funds and large institutions have $204M invested in Opus Genetics in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

367% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 6

265% more capital invested

Capital invested by funds: $55.9M → $204M (+$148M)

34% more funds holding

Funds holding: 5979 (+20)

23.5% more ownership

Funds ownership: 40.33%63.83% (+23%)

7% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
79
Holders Change
+20
Holders Change %
+33.9%
% of All Funds
0.97%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
28
Increased
16
Reduced
15
Closed
6
Calls
$897K
Puts
Net Calls
+$897K
Net Calls Change
+$723K
Name Holding Trade Value Shares
Change
Change in
Stake
SS
76
SBI Securities
Japan
$2.41K -$7.07K -2,044 -79%
Fidelity Investments
77
Fidelity Investments
Massachusetts
$36 +$28 +8 New
AF
78
Allworth Financial
California
$23
VC
79
Voss Capital
Texas
-$888K -441,891 Closed
Qube Research & Technologies (QRT)
80
Qube Research & Technologies (QRT)
United Kingdom
-$80.4K -39,978 Closed
JIC
81
Johnson Investment Counsel
Ohio
-$40.2K -20,000 Closed
VF
82
Virtu Financial
New York
-$34K -16,810 Closed
OQS
83
Occudo Quantitative Strategies
Florida
-$24.5K -12,205 Closed
Citigroup
84
Citigroup
New York
-$997 -496 Closed
Royal Bank of Canada
85
Royal Bank of Canada
Ontario, Canada
-$1.02K -294 -98%

IRD Hedge Fund Activity: Q1 2026 in Review

79 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q1 2026, worth a combined $204M — up 265% from $55.9M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new IRD positions and 6 closed out — a net gain of 22 holders — while 16 added to existing stakes and 15 trimmed.

The largest buyer was Caligan Partners, opening a new position worth an estimated $21M. The largest seller was Nantahala Capital Management, cutting an estimated $10.7M.

  • 79 institutional investors held Opus Genetics (IRD) as of Q1 2026, up from 59 in Q4 2025.
  • Funds reported $204M of Opus Genetics stock for Q1 2026, up 265% quarter-over-quarter.
  • 28 funds opened new Opus Genetics positions in Q1 2026 and 6 closed out, a net change of +22 holders.
  • The largest Opus Genetics buyer in Q1 2026 was Caligan Partners, an estimated $21M added.
  • The largest Opus Genetics seller in Q1 2026 was Nantahala Capital Management, an estimated $10.7M sold.

Based on aggregated 13F filings for Q1 2026.